Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hologic and Cytyc complete merger
Hologic will continue to trade on the Nasdaq Global Select Market under the symbol HOLX while Cytyc will become a wholly-owned subsidiary of Hologic. Under the terms of
Hologic will continue to trade on the Nasdaq Global Select Market under the symbol HOLX while Cytyc will become a wholly-owned subsidiary of Hologic. Under the terms of
One of the objectives of the exclusive licensing agreement is to evaluate the safety and efficacy of treating stroke patients with caffeinol, administered by intravenous infusion, in combination
Renvela is a next-generation version of Renagel (sevelamer hydrochloride), the most-prescribed phosphate binder in the US. Genzyme expects to launch Renvela for dialysis patients in the US during
Bioenvision shares have now ceased trading and the company will be delisted from Nasdaq. In total, 56% of Bioenvision’s issued and outstanding shares of common stock and preferred
DepoDur, which was developed by and licensed from Pacira Pharmaceuticals, utilizes Pacira’s DepoFoam technology and is a novel, single dose modified-release formulation of morphine. The approved indication in
The Menactra vaccine is the first and only quadrivalent conjugate vaccine licensed in the US for the prevention of meningococcal disease. Menactra vaccine offers protection against Neisseria meningitidis
The drug is currently awaiting FDA approval. Under the terms of the agreement, Solvay will provide sales support in the US, contribute to development and promotional expenses and
The Phase IIb trial was an in-clinic evaluation of tezampanel in patients suffering a single migraine attack, with or without aura. The clinical trial was designed as a
The primary endpoint of the trial is to determine the proportion of patients given phenoxodiol that have a 50% post-therapy prostate specific antigen (PSA) decline at 12 weeks
The new regimens with Januvia described in the updated labeling include, as an adjunct to diet and exercise, initial therapy in combination with metformin; add-on therapy to a